Currently, there is no FDA-approved therapeutics available for NAFLD, although several classes of drugs for NAFLD/NASH treatment are under development, (i.e., FXR agonists and PPAR agonists) [31]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.